To obtain an assessment of the activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate on the circulating levels of prostate-specific antigen (PSA). [ Time Frame: Visits 1, 10, follow-up visits, discontinuation visit ] [ Designated as safety issue: No ]

To investigate safety, tolerability, MTD (and/or biologically-effective dose(s) or maximum feasible dose) and PK of AZD3514 and abiraterone when administered in combination, in patients who have not received prior treatment with abiraterone acetate [ Time Frame: At every visit ] [ Designated as safety issue: No ]

To compare the PK of AZD3514 monotherapy in patients who have been fed or fasted before the administration of study treatment [ Time Frame: At visits 2 and 4 ] [ Designated as safety issue: No ]

To investigate the effect of AZD3514 on biomarkers of AR expression in paired pre- and post-dose tumour biopsies. [ Time Frame: July 2012 - Feb 2013 ] [ Designated as safety issue: No ]

Have bone or soft tissue lesions that are suitable for paired biopsy sampling

Exclusion Criteria:

Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAEv4) grade 1 except for alopecia or toxicities related to the use of gonadotropin-releasing hormone agonists

Medically important spinal cord compression or brain metastases

Medically important evidence of severe or uncontrolled systemic disease

History of hypersensitivity to active or inactive excipients of AZD3514 or drugs with a similar chemical structure or class to AZD3514

Any medically important factors identified from electrocardiogram (ECG) measurements

Concurrent or recent treatment with certain medications or medical procedures

The following criteria exclude patients from entering the AZD3514 administered in combination with abiraterone acetate cohort(s):

As judged by the investigator, any evidence of severe or uncontrolled systemic diseases or conditions, including adrenocortical insufficiency or a history of cardiovascular disease including heart failure (currently there are no randomized data for the use of abiraterone acetate in patients with LVEF < 50% or NYHA Class III or IV heart failure), which would make it undesirable for the patient to participate in the trial. See the full local prescribing information for abiraterone acetate for more detail

Child-Pugh class B and C hepatic impairment

If unable to fast for ≥ 2 hours prior to taking a dose to ≥ 1 hour post dose

Received abiraterone acetate treatment previously

Known hypersensitivity to components of prednisone or prednisolone

Any systemic fungal infections

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01162395